Insider Selling: Alignment Healthcare (NASDAQ:ALHC) Insider Sells 11,602 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Andreas Wagner sold 11,602 shares of the firm’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $18.22, for a total value of $211,388.44. Following the completion of the transaction, the insider directly owned 148,628 shares in the company, valued at $2,708,002.16. The trade was a 7.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Alignment Healthcare Stock Performance

Shares of NASDAQ:ALHC traded down $0.03 during trading on Thursday, hitting $18.16. The company’s stock had a trading volume of 3,987,587 shares, compared to its average volume of 2,967,147. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.71 and a quick ratio of 1.71. The firm has a market cap of $3.71 billion, a price-to-earnings ratio of -1,814.19, a P/E/G ratio of 2.62 and a beta of 1.18. The company has a 50-day moving average of $20.57 and a 200-day moving average of $18.78. Alignment Healthcare, Inc. has a 12 month low of $11.63 and a 12 month high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last announced its earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period in the prior year, the company earned ($0.16) earnings per share. The firm’s revenue was up 44.4% on a year-over-year basis. On average, sell-side analysts expect that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the company. KeyCorp restated an “overweight” rating and issued a $28.00 price target on shares of Alignment Healthcare in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. JPMorgan Chase & Co. lifted their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Piper Sandler upped their price target on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Finally, UBS Group raised their price objective on shares of Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.56.

Institutional Investors Weigh In On Alignment Healthcare

Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its position in shares of Alignment Healthcare by 92.6% during the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock valued at $1,720,000 after buying an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Alignment Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after acquiring an additional 2,594 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Alignment Healthcare by 79.1% during the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after acquiring an additional 429,703 shares during the last quarter. Woodline Partners LP purchased a new position in Alignment Healthcare during the first quarter valued at $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Alignment Healthcare by 16.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock valued at $5,729,000 after acquiring an additional 44,452 shares in the last quarter. 86.19% of the stock is owned by hedge funds and other institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.